TABLE 1.
Characteristics of the patients at baseline
| Characteristic | Patients, n (%) |
|---|---|
| Total patients | 21 (100%) |
| Median age, years (range) | 55 (23‐72) |
| Sex | |
| Male | 13 (61.9%) |
| Female | 8 (38.1%) |
| Disease stage | |
| I‐II | 3 (14.3%) |
| III‐IV | 18 (85.7%) |
| NCCN‐IPI group | |
| Low‐intermediate: 2‐3 | 6 (28.6%) |
| High‐intermediate: 4‐5 | 13 (61.9%) |
| High: ≥6 | 2 (9.5%) |
| Extranodal disease | 6 (28.6%) |
| BM involved | 5 (23.8%) |
| CNS involved | 3 (14.3%) |
| Bulky | 5 (23.8%) |
| Cell of origin | |
| GCB | 16 (76.2%) |
| NON‐GCB | 5 (23.8%) |
| MCY/BCL2 DE | 4 (19.0%) |
| Refractory DLBCL | 15 (71.4%) |
| Median previous therapies (range) | 3 (1‐6) |
| Conditioning therapy | |
| FC | 19 (90.5%) |
| Others | 2 (9.5%) |
Abbreviations: BM, bone marrow; CNS, central nervous system; DE, double expression; FC, fludarabine and cyclophosphamide; GCB, germinal center B cell; NCCN‐IPI, National Comprehensive Cancer Network‐International Prognostic Index.